Aa
90% sure of exposure but s/co negative
I am about 90% sure I accidently shared a needle with a known hcv positive individual (long story and not really relavent). Anyways 8 weeks later s/co is negative at 0.6 with 1+ being positive I think. Ive been tested before and I asked my doc what the s/co was on previous test and he said 0... I know it can takes several months to test positive on these things.. But my question is: does an increasing s/co indicate growing antibodies, or does s/co under 1 mean nothing at all except negative?
"Anyways 8 weeks later s/co is negative at 0.6 with 1+ being positive I think."
What test did you have? I posted some of the tests above and as you can see the s/co with the lowest value is ≥ 3.8
"I know it can takes several months to test positive on these things"
If a person exposed to hepatitis C becomes infected, virus particles (called HCV RNA) can be detected within 1-2 weeks. Liver function tests also will tend to rise during this timeframe. Hepatitis C antibodies appear after RNA is detectable and can take 3-12 weeks to appear.
http://www.hepatitis.va.gov/patient/testing/time-required-to-test-positive.asp
____________________________________________________
"does s/co under 1 mean nothing at all except negative? "
That is my understanding of it based on the tests Im aware of and there s/co's
What test did you have? I posted some of the tests above and as you can see the s/co with the lowest value is ≥ 3.8
"I know it can takes several months to test positive on these things"
If a person exposed to hepatitis C becomes infected, virus particles (called HCV RNA) can be detected within 1-2 weeks. Liver function tests also will tend to rise during this timeframe. Hepatitis C antibodies appear after RNA is detectable and can take 3-12 weeks to appear.
http://www.hepatitis.va.gov/patient/testing/time-required-to-test-positive.asp
____________________________________________________
"does s/co under 1 mean nothing at all except negative? "
That is my understanding of it based on the tests Im aware of and there s/co's
Screening Test
Ortho HCV Version 3.0 ELISA Test System Ortho EIA
(Enzyme Immunoassay) ≥ 3.8
Abbott HCV EIA 2.0 Abbott EIA
(Enzyme Immunoassay) ≥ 3.8
VITROS Anti-HCV Ortho CIA
(Chemiluminescennt Immunoassay) ≥ 8.0
AxSYM Anti-HCV Abbott MEIA
(Microparticle Immunoassay) ≥ 10.0
Architect Anti-HCV Abbott CMIA
(Chemiluminescent Microparticle Immunoassay) ≥ 5.0
Advia Centaur HCV Bayer CIA
(Chemiluminescennt Immunoassay) ≥ 11.0
Signal-to-Cut–Off Ratios for Commercially Available Assays
CDC has recommended that a person be considered to have serologic evidence of HCV infection only after an anti-HCV screening-test-positive result has been verified by a more specific serologic test (e.g., RIBA) or a nucleic acid test (NAT). This more specific, supplemental testing is necessary, particularly in populations with a lower prevalence of disease, to identify and exclude false positive screening test results. However, currently, the majority of laboratories report positive anti-HCV results based on a positive screening assay alone.
The recommended anti-HCV testing algorithm has been expanded to include an option that uses the signal-to-cut–off (s/co) ratios of screening-test--positive results. This can serve as an alternative to a supplemental test in some circumstances, minimizing the number of specimens that require supplemental testing and providing a result that has a high probability of reflecting the person's true antibody status.
Signal-to-cut–off ratios are calculated by dividing the optical density (OD) value of the sample being tested by the OD value of the assay cut-off for that run. Analysis of enzyme immunoassay and chemiluminescence assay data indicates that s/co ratios can be used to predict supplemental test-positive results. A specific s/co ratio can be identified for each test that would predict a true antibody-positive result (as defined by the results of supplemental testing) ≥95% of the time, regardless of the anti-HCV prevalence or characteristics of the population being tested.
Implementation of these recommendations will provide more reliable results for physicians and their patients, so that further counseling and clinical evaluation are limited to those confirmed to have been infected with HCV. This is especially critical for persons being tested for HCV infection for the first time, for persons being tested in non-clinical settings, and for those being tested to determine the need for medical referral. Implementation of these recommendations also will improve public health surveillance systems.
http://www.cdc.gov/hepatitis/HCV/LabTesting.htm
Ortho HCV Version 3.0 ELISA Test System Ortho EIA
(Enzyme Immunoassay) ≥ 3.8
Abbott HCV EIA 2.0 Abbott EIA
(Enzyme Immunoassay) ≥ 3.8
VITROS Anti-HCV Ortho CIA
(Chemiluminescennt Immunoassay) ≥ 8.0
AxSYM Anti-HCV Abbott MEIA
(Microparticle Immunoassay) ≥ 10.0
Architect Anti-HCV Abbott CMIA
(Chemiluminescent Microparticle Immunoassay) ≥ 5.0
Advia Centaur HCV Bayer CIA
(Chemiluminescennt Immunoassay) ≥ 11.0
Signal-to-Cut–Off Ratios for Commercially Available Assays
CDC has recommended that a person be considered to have serologic evidence of HCV infection only after an anti-HCV screening-test-positive result has been verified by a more specific serologic test (e.g., RIBA) or a nucleic acid test (NAT). This more specific, supplemental testing is necessary, particularly in populations with a lower prevalence of disease, to identify and exclude false positive screening test results. However, currently, the majority of laboratories report positive anti-HCV results based on a positive screening assay alone.
The recommended anti-HCV testing algorithm has been expanded to include an option that uses the signal-to-cut–off (s/co) ratios of screening-test--positive results. This can serve as an alternative to a supplemental test in some circumstances, minimizing the number of specimens that require supplemental testing and providing a result that has a high probability of reflecting the person's true antibody status.
Signal-to-cut–off ratios are calculated by dividing the optical density (OD) value of the sample being tested by the OD value of the assay cut-off for that run. Analysis of enzyme immunoassay and chemiluminescence assay data indicates that s/co ratios can be used to predict supplemental test-positive results. A specific s/co ratio can be identified for each test that would predict a true antibody-positive result (as defined by the results of supplemental testing) ≥95% of the time, regardless of the anti-HCV prevalence or characteristics of the population being tested.
Implementation of these recommendations will provide more reliable results for physicians and their patients, so that further counseling and clinical evaluation are limited to those confirmed to have been infected with HCV. This is especially critical for persons being tested for HCV infection for the first time, for persons being tested in non-clinical settings, and for those being tested to determine the need for medical referral. Implementation of these recommendations also will improve public health surveillance systems.
http://www.cdc.gov/hepatitis/HCV/LabTesting.htm
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
